ICUI icon

ICU Medical

114.13 USD
--2.76
2.36%
At close Updated Oct 10, 4:00 PM EDT
1 day
-2.36%
5 days
-6.66%
1 month
-14.55%
3 months
-16.85%
6 months
-17.55%
Year to date
-27.76%
1 year
-35.53%
5 years
-42.31%
10 years
8.36%
 

About: ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Employees: 15,000

0
Funds holding %
of 7,491 funds
0
Analysts bullish %
of 2 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,314% more call options, than puts

Call options by funds: $4.67M | Put options by funds: $330K

58% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 79

2.76% more ownership

Funds ownership: 99.15% [Q1] → 101.91% (+2.8%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (0) [Q2]

2% less capital invested

Capital invested by funds: $3.38B [Q1] → $3.31B (-$67.7M) [Q2]

3% less funds holding

Funds holding: 281 [Q1] → 272 (-9) [Q2]

17% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 41

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$153
34% upside
Avg. target
$167
46% upside
High target
$180
58% upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%

Financial journalist opinion

Neutral
Seeking Alpha
1 month ago
ICU Medical, Inc. (ICUI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
ICU Medical, Inc. (NASDAQ:ICUI ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Vivek Jain - CEO & Chairman of the Board Presentation Unknown Analyst Did you give me the disclosure? Did you say anything more?
ICU Medical, Inc. (ICUI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Negative
Zacks Investment Research
1 month ago
FDA Identifies ICU Medical's Plum Duo Recall as Serious Type
ICUI faces an FDA recall of its Plum Duo Infusion System over software flaws, though devices remain in use, pending fixes.
FDA Identifies ICU Medical's Plum Duo Recall as Serious Type
Neutral
GlobeNewsWire
1 month ago
ICU Medical to Participate in Upcoming Investor Conferences
SAN CLEMENTE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences in September:
ICU Medical to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
2 months ago
ICU Medical, Inc. (ICUI) Q2 2025 Earnings Call Transcript
ICU Medical, Inc. (NASDAQ:ICUI ) Q2 2025 Earnings Call August 7, 2025 4:30 PM ET Company Participants Brian Michael Bonnell - CFO & Treasurer Vivek Jain - CEO & Chairman of the Board Conference Call Participants Charles S. Strauzer - CJS Securities, Inc. Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Michael Toomey - Jefferies LLC, Research Division Michael Stephen Matson - Needham & Company, LLC, Research Division William Korner - Unidentified Company John Mills - ICR Inc. Operator Good afternoon, everyone, and welcome to today's ICU Medical Second Quarter 2025 Earnings Conference Call.
ICU Medical, Inc. (ICUI) Q2 2025 Earnings Call Transcript
Positive
The Motley Fool
2 months ago
ICU Medical (ICUI) Q2 EPS Jumps 40%
ICU Medical (ICUI 2.40%), a medical device company specializing in infusion therapy and related products, released its second quarter results on August 7, 2025. The most important news from the report was a significant earnings per share (EPS) beat, with adjusted EPS of $2.10 (Non-GAAP) compared to analyst expectations of $1.50, a positive difference of 40.0% (Non-GAAP).
ICU Medical (ICUI) Q2 EPS Jumps 40%
Positive
Zacks Investment Research
2 months ago
ICU Medical (ICUI) Surpasses Q2 Earnings and Revenue Estimates
ICU Medical (ICUI) came out with quarterly earnings of $2.1 per share, beating the Zacks Consensus Estimate of $1.44 per share. This compares to earnings of $1.56 per share a year ago.
ICU Medical (ICUI) Surpasses Q2 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025.
ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
Neutral
GlobeNewsWire
2 months ago
ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call
SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2025 earnings release and conference call.
ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call
Neutral
PRNewsWire
4 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI
NEW YORK , June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc. ("ICU" or the "Company") (NASDAQ: ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI
Neutral
Accesswire
4 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc.("ICU" or the "Company") (NASDAQ:ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI
Price charts implemented using Lightweight Charts™